{
    "Trade/Device Name(s)": [
        "LIQUID CO2-2",
        "LCO2-2"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K152085",
    "Predicate Device Reference 510(k) Number(s)": [
        "K100289"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KHS"
    ],
    "Summary Letter Date": "January 20, 2015",
    "Summary Letter Received Date": "January 27, 2015",
    "Submission Date": "February 9, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1160"
    ],
    "Regulation Name(s)": [
        "Bicarbonate/carbon dioxide test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Carbon Dioxide"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "RX Daytona plus"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Laboratories LIQUID CO2-2 (LCO2-2) enzymatic assay for quantitative determination of carbon dioxide in serum and plasma",
    "Indications for Use Summary": "For the quantitative in vitro determination of carbon dioxide in serum and plasma to aid in diagnosis and treatment of disorders associated with acid-base balance",
    "fda_folder": "Clinical Chemistry"
}